Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector
Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue to be subject to Chinese import tariffs.
You may also be interested in...
NPA sounds alarm on Trump administration tariffs on $200bn in Chinese goods scheduled for October. In letter US Trade Representative, NPA President and CEO Daniel Fabricant asks the agency to exempt 57 items from the Harmonized Tariff Schedule that would impact hundreds of dietary ingredients.
Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.